CheckMyRecalls

10,013 recalls · updated 20 Nov 2026

Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release…

Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules

Read the official FDA notice

Published
9 Apr 2025
Units affected
14,863 bottles
Agency
FDA
Country
United States

The hazard

CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx Only, 1,000 Capsules per bottle, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical, Inc., Berkley Heights, NJ 07922, NDC 51991-747-10.

Brand / company
Breckenridge Pharmaceutical, Inc.
Codes / lots
Lot 240909C, Exp Date 03/31/2027
Distribution
Nationwide in the US
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 9 Apr 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.